Omega-3 Fatty Acids for Heart Health: A Comprehensive Evidence Review
Last reviewed: 11:53 Ngày 21 tháng 3 năm 2026
Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), represent the most extensively studied cardiovascular supplements in history. The research trajectory spans over four decades, beginning with epidemiological observations of low cardiovascular mortality in Greenland Inuit populations with high fish consumption. Since then, numerous randomized controlled trials involving hundreds of thousands of participants have evaluated omega-3 supplementation for cardiovascular outcomes. The evidence landscape, however, is more nuanced than commonly presented, with significant differences between earlier and more recent trials, and between different formulations and dosages.
The landmark GISSI-Prevenzione trial (1999) demonstrated that 1 gram daily of EPA+DHA reduced total mortality by 20% and sudden cardiac death by 45% in post-myocardial infarction patients. However, subsequent large trials including ORIGIN (2012), Risk and Prevention (2013), and ASCEND (2018) failed to replicate these benefits with standard-dose (1 gram) omega-3 supplementation. This apparent discrepancy likely reflects improvements in background cardiovascular care (widespread statin use, better blood pressure control) in the intervening years, as well as higher baseline omega-3 intake in some study populations. These null results led many cardiology guidelines to temper their recommendations for omega-3 supplements.
The evidence landscape shifted dramatically with the REDUCE-IT trial (2019), which tested icosapent ethyl (a purified EPA formulation) at 4 grams daily in statin-treated patients with elevated triglycerides. This trial demonstrated a striking 25% relative risk reduction in major adverse cardiovascular events (MACE) — including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and unstable angina. The magnitude of benefit exceeded what would be predicted from triglyceride lowering alone, suggesting additional anti-inflammatory and plaque-stabilizing mechanisms. However, the STRENGTH trial (2020), which tested a combined EPA+DHA formulation at 4 grams daily, did not show cardiovascular benefit, igniting debate about whether EPA alone is superior to EPA+DHA combinations or whether differences in mineral oil placebo effects confounded the REDUCE-IT results.
Current evidence supports the following conclusions. For triglyceride reduction, prescription omega-3 formulations at doses of 2-4 grams daily are effective and FDA-approved. For general cardiovascular prevention in the general population, standard-dose omega-3 supplements (1 gram) have not demonstrated consistent benefits in the modern era of optimized cardiovascular care. The American Heart Association recommends consuming fish (particularly fatty fish) at least twice weekly as part of a heart-healthy diet, which provides roughly 500 mg daily of EPA+DHA. For individuals with established cardiovascular disease, elevated triglycerides, or heart failure, higher-dose omega-3 supplementation should be discussed with a cardiologist who can evaluate the specific formulation and dosage appropriate for your clinical situation. Potential side effects include fishy aftertaste, gastrointestinal symptoms, and a small increase in bleeding time at higher doses.
The landmark GISSI-Prevenzione trial (1999) demonstrated that 1 gram daily of EPA+DHA reduced total mortality by 20% and sudden cardiac death by 45% in post-myocardial infarction patients. However, subsequent large trials including ORIGIN (2012), Risk and Prevention (2013), and ASCEND (2018) failed to replicate these benefits with standard-dose (1 gram) omega-3 supplementation. This apparent discrepancy likely reflects improvements in background cardiovascular care (widespread statin use, better blood pressure control) in the intervening years, as well as higher baseline omega-3 intake in some study populations. These null results led many cardiology guidelines to temper their recommendations for omega-3 supplements.
The evidence landscape shifted dramatically with the REDUCE-IT trial (2019), which tested icosapent ethyl (a purified EPA formulation) at 4 grams daily in statin-treated patients with elevated triglycerides. This trial demonstrated a striking 25% relative risk reduction in major adverse cardiovascular events (MACE) — including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and unstable angina. The magnitude of benefit exceeded what would be predicted from triglyceride lowering alone, suggesting additional anti-inflammatory and plaque-stabilizing mechanisms. However, the STRENGTH trial (2020), which tested a combined EPA+DHA formulation at 4 grams daily, did not show cardiovascular benefit, igniting debate about whether EPA alone is superior to EPA+DHA combinations or whether differences in mineral oil placebo effects confounded the REDUCE-IT results.
Current evidence supports the following conclusions. For triglyceride reduction, prescription omega-3 formulations at doses of 2-4 grams daily are effective and FDA-approved. For general cardiovascular prevention in the general population, standard-dose omega-3 supplements (1 gram) have not demonstrated consistent benefits in the modern era of optimized cardiovascular care. The American Heart Association recommends consuming fish (particularly fatty fish) at least twice weekly as part of a heart-healthy diet, which provides roughly 500 mg daily of EPA+DHA. For individuals with established cardiovascular disease, elevated triglycerides, or heart failure, higher-dose omega-3 supplementation should be discussed with a cardiologist who can evaluate the specific formulation and dosage appropriate for your clinical situation. Potential side effects include fishy aftertaste, gastrointestinal symptoms, and a small increase in bleeding time at higher doses.